BIOMAT Database Logo BIOMAT Database Logo

Viral load, viral phenotype modification, zidovudine susceptibility and reverse transcriptase mutations during the first 6 months of zidovudine monotherapy in HIV-1-infected people. 1996

S Rusconi, and M P De Pasquale, and F Mainini, and E Bulgheroni, and S Kurtagic, and A Gori, and M Violin, and N Zanchetta, and M Moroni, and C Balotta, and M Galli
Clinica delle Malattie Infettive, Universitá di Milano, Ospedale Luigi Sacco, Italy. rusconi@imiucca.csi.unimi.it

We studied 14 zidovudine-naive, HIV-1-infected patients attending an infectious diseases clinic in Milan during zidovudine therapy for 6 months. We monitored CD4 cell counts, immune complex-dissociated p24 antigen, viral phenotype and viral load in plasma. The virus infecting a subset of patients was examined for zidovudine susceptibility and zidovudine resistance-associated mutations. A significant correlation was established between the increase in the CD4 cell count and the decrease in viral load (Spearman's coefficients < -0.5). Patients who were p24 antigen positive had a higher viral load (P < 0.005 at baseline and after 6 months of therapy). Patients with non-syncytium-inducing (NSI) virus had higher CD4 cell counts over time than those with syncytium-inducing (SI) virus. We also examined the viral load in relation to viral phenotype. The median viral load in patients with NSI virus was higher than in SI controls at baseline, but not after 3 and 6 months of therapy. Sequential isolates of HIV-1 were obtained from nine patients and tested for resistance to zidovudine by monitoring the drug susceptibility and the reverse transcriptase-encoding sequence. Amino acid changes at codons 70 and 215 were present in some but not all isolates with zidovudine-resistant phenotype in vitro. It was possible to perform a correlation between zidovudine susceptibility and zidovudine-associated pol gene mutations only at the 6-month time point (Spearman's coefficient = 0.076). SI phenotype was associated with the development of a decreased zidovudine susceptibility. A correlation between zidovudine-associated pol gene mutations and SI phenotype was detected at the 6-month time point.

UI MeSH Term Description Entries
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D016655 HIV Core Protein p24 A major core protein of the human immunodeficiency virus encoded by the HIV gag gene. HIV-seropositive individuals mount a significant immune response to p24 and thus detection of antibodies to p24 is one basis for determining HIV infection by ELISA and Western blot assays. The protein is also being investigated as a potential HIV immunogen in vaccines. HIV Major Core Protein p24,HIV gag Gene Product p24,HIV p24 Antigen,gag Protein p24, HIV,p24(HIV),HIV Protein p24,HTLV-III p24,p24 protein, Human Immunodeficiency Virus,HTLV III p24,p24 Antigen, HIV,p24, HIV Protein,p24, HTLV-III
D054303 HIV Reverse Transcriptase A reverse transcriptase encoded by the POL GENE of HIV. It is a heterodimer of 66 kDa and 51 kDa subunits that are derived from a common precursor protein. The heterodimer also includes an RNAse H activity (RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS) that plays an essential role the viral replication process. Reverse Transcriptase, HIV,Reverse Transcriptase, Human Immunodeficiency Virus,Transcriptase, HIV Reverse
D018791 CD4 Lymphocyte Count The number of CD4-POSITIVE T-LYMPHOCYTES per unit volume of BLOOD. Determination requires the use of a fluorescence-activated flow cytometer. Lymphocyte Count, CD4,T4 Lymphocyte Count,CD4 Cell Counts,CD4 Counts,CD4+ Cell Counts,CD4+ Counts,CD4 Cell Count,CD4 Count,CD4 Lymphocyte Counts,CD4+ Cell Count,CD4+ Count,Count, T4 Lymphocyte,Counts, T4 Lymphocyte,Lymphocyte Count, T4,Lymphocyte Counts, CD4,Lymphocyte Counts, T4,T4 Lymphocyte Counts

Related Publications

S Rusconi, and M P De Pasquale, and F Mainini, and E Bulgheroni, and S Kurtagic, and A Gori, and M Violin, and N Zanchetta, and M Moroni, and C Balotta, and M Galli
Zidovudine resistance reverse transcriptase mutations during didanosine monotherapy.
August 1996, The Journal of infectious diseases,
S Rusconi, and M P De Pasquale, and F Mainini, and E Bulgheroni, and S Kurtagic, and A Gori, and M Violin, and N Zanchetta, and M Moroni, and C Balotta, and M Galli
Reverse transcriptase mutations in HIV-1-infected children treated with zidovudine.
October 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association,
S Rusconi, and M P De Pasquale, and F Mainini, and E Bulgheroni, and S Kurtagic, and A Gori, and M Violin, and N Zanchetta, and M Moroni, and C Balotta, and M Galli
Analysis of HIV-1 reverse transcriptase gene mutations in infected children treated with zidovudine.
November 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association,
S Rusconi, and M P De Pasquale, and F Mainini, and E Bulgheroni, and S Kurtagic, and A Gori, and M Violin, and N Zanchetta, and M Moroni, and C Balotta, and M Galli
Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali.
January 2010, The Journal of antimicrobial chemotherapy,
S Rusconi, and M P De Pasquale, and F Mainini, and E Bulgheroni, and S Kurtagic, and A Gori, and M Violin, and N Zanchetta, and M Moroni, and C Balotta, and M Galli
The K65R reverse transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutations.
January 2006, Antiviral therapy,
S Rusconi, and M P De Pasquale, and F Mainini, and E Bulgheroni, and S Kurtagic, and A Gori, and M Violin, and N Zanchetta, and M Moroni, and C Balotta, and M Galli
Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudine in HIV-1-infected adults with no prior antiretroviral therapy.
March 2002, Antiviral therapy,
S Rusconi, and M P De Pasquale, and F Mainini, and E Bulgheroni, and S Kurtagic, and A Gori, and M Violin, and N Zanchetta, and M Moroni, and C Balotta, and M Galli
Analysis of the Zidovudine Resistance Mutations T215Y, M41L, and L210W in HIV-1 Reverse Transcriptase.
December 2015, Antimicrobial agents and chemotherapy,
S Rusconi, and M P De Pasquale, and F Mainini, and E Bulgheroni, and S Kurtagic, and A Gori, and M Violin, and N Zanchetta, and M Moroni, and C Balotta, and M Galli
Zidovudine (AZT) monotherapy selects for the A360V mutation in the connection domain of HIV-1 reverse transcriptase.
January 2012, PloS one,
S Rusconi, and M P De Pasquale, and F Mainini, and E Bulgheroni, and S Kurtagic, and A Gori, and M Violin, and N Zanchetta, and M Moroni, and C Balotta, and M Galli
Zidovudine treatment is not associated with HTLV-1 reverse transcriptase gene mutations in HTLV-I/HIV-1 co-infected patients.
April 1997, Antiviral therapy,
S Rusconi, and M P De Pasquale, and F Mainini, and E Bulgheroni, and S Kurtagic, and A Gori, and M Violin, and N Zanchetta, and M Moroni, and C Balotta, and M Galli
Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).
December 1989, Science (New York, N.Y.),
Copied contents to your clipboard!